Immunophenotypic abnormality quantification refines multiparameter flow cytometry-based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission.

ABSTRACT: Flow cytometry-based measurable residual disease (MRD) testing is routinely used in acute myeloid leukemia (AML), but methodologies need refinement to optimize assay characteristics. Here, we examined 1215 adults with AML or myelodysplastic syndrome/AML allografted in morphologic remission to study how the type(s) of leukemic blasts and degree/number of immunophenotypic abnormalities could improve MRD testing. Among 233 patients with pre-hematopoietic cell transplantation (pre-HCT) MRD, 80 (34%) had non-stem cell-like (NSC-like) leukemic blasts, 109 (47%) had stem cell-like (SC-like) leukemic blasts, and 44 (19%) had NSC- and SC-like leukemic blast cell populations. Across all MRD^pos patients, a higher degree/number of immunophenotypic abnormalities was associated with increased

SUBMITTER: Le CM 

PROVIDER: S-EPMC12854164 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature